Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients

LEVODOPA-INDUCED DYSKINESIA IN PARKINSON'S: A LONGITUDINAL PET STUDY

(2016) Andreas-Antonios Roussakis et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

(2015) Pietro Iaffaldano et al.   BRAIN

Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients – preliminary study

(2015) Julia Rudnicka et al.   Central European Journal of Immunology

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process

(2015) Àlex Rovira et al.   Nature Reviews Neurology

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

(2015)   Nature Reviews Neurology

Switching from natalizumab to fingolimod

(2015) Ludwig Kappos et al.   NEUROLOGY

Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab

(2014) T. Koudriavtseva et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Fingolimod after natalizumab and the risk of short-term relapse

(2014) V. G. Jokubaitis et al.   NEUROLOGY

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

(2014) R. J. Fox et al.   NEUROLOGY

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Switching From Natalizumab to Fingolimod in Multiple Sclerosis

(2014) Mikael Cohen et al.   JAMA Neurology

Reduction of the washout time between natalizumab and fingolimod

(2013) Jérôme de Seze et al.   Multiple Sclerosis Journal

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

(2012) Anke Vennegoor et al.   Multiple Sclerosis Journal

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody

(2011) Theo Rispens et al.   ANALYTICAL BIOCHEMISTRY

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

(2011) Theo Rispens et al.   Multiple Sclerosis Journal

Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated

(2010) Joep Killestein et al.   ANNALS OF NEUROLOGY

Effects of Natalizumab on Circulating B Cells, T Regulatory Cells and Natural Killer Cells

(2010) Norman Putzki et al.   EUROPEAN NEUROLOGY

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

(2009) B. O. Khatri et al.   NEUROLOGY

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

(2008) F. Zohren et al.   BLOOD

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab

(2008) H. Bonig et al.   BLOOD

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis

(2008) M. Krumbholz et al.   NEUROLOGY

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

(2008) M. Mehling et al.   NEUROLOGY